These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 20628372)

  • 1. CD40-activated B cells contribute to mesothelioma tumor regression.
    Jackaman C; Cornwall S; Graham PT; Nelson DJ
    Immunol Cell Biol; 2011 Feb; 89(2):255-67. PubMed ID: 20628372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
    Jackaman C; Nelson DJ
    Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation.
    Stumbles PA; Himbeck R; Frelinger JA; Collins EJ; Lake RA; Robinson BW
    J Immunol; 2004 Nov; 173(10):5923-8. PubMed ID: 15528325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
    Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
    Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.
    Wennhold K; Thelen M; Schlößer HA; Haustein N; Reuter S; Garcia-Marquez M; Lechner A; Kobold S; Rataj F; Utermöhlen O; Chakupurakal G; Theurich S; Hallek M; Abken H; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Cancer Immunol Res; 2017 Sep; 5(9):730-743. PubMed ID: 28778961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
    Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
    Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.
    McDonnell AM; Lesterhuis WJ; Khong A; Nowak AK; Lake RA; Currie AJ; Robinson BW
    Eur J Immunol; 2015 Jan; 45(1):49-59. PubMed ID: 25316312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
    Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
    Carpenter EL; Mick R; Rüter J; Vonderheide RH
    J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
    Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
    Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study.
    Johnson P; Challis R; Chowdhury F; Gao Y; Harvey M; Geldart T; Kerr P; Chan C; Smith A; Steven N; Edwards C; Ashton-Key M; Hodges E; Tutt A; Ottensmeier C; Glennie M; Williams A
    Clin Cancer Res; 2015 Mar; 21(6):1321-8. PubMed ID: 25589626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
    Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
    J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity.
    Morrison AH; Diamond MS; Hay CA; Byrne KT; Vonderheide RH
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8022-8031. PubMed ID: 32213589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
    Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
    J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myoinjury transiently activates muscle antigen-specific CD8+ T cells in lymph nodes in a mouse model.
    Liao H; Franck E; Fréret M; Adriouch S; Baba-Amer Y; Authier FJ; Boyer O; Gherardi RK
    Arthritis Rheum; 2012 Oct; 64(10):3441-51. PubMed ID: 22674045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
    Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
    Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD40-activated B cells induce anti-tumor immunity in vivo.
    Wennhold K; Weber TM; Klein-Gonzalez N; Thelen M; Garcia-Marquez M; Chakupurakal G; Fiedler A; Schlösser HA; Fischer R; Theurich S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M
    Oncotarget; 2017 Apr; 8(17):27740-27753. PubMed ID: 26934557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines.
    Kobie JJ; Wu RS; Kurt RA; Lou S; Adelman MK; Whitesell LJ; Ramanathapuram LV; Arteaga CL; Akporiaye ET
    Cancer Res; 2003 Apr; 63(8):1860-4. PubMed ID: 12702574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
    Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
    J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.